Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 11, 2010, Pages 1192-1199

  Guarner Argente, C ^a   Sanchez E ^a   Vidal, S ^a   RomAn E ^a   ConcepciOn M ^a   Poca, M ^a   Sanchez D ^a   Juarez C ^a   Soriano, G ^a   Guarner, C ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 4;

AGED; ARTICLE; ASCITES; BACTEREMIA; BACTERIAL INFECTION; DISEASE COURSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; EPIDEMIOLOGIC METHODS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 77951800129     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04291.x     Document Type: Article

References (42)

1. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008 28 : 26 42.
2. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005 54 : 718 725.
3. Fernández J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002 35 : 140 148.
4. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005 17 : 27 31.
5. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005 5 : 156 164.
6. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 2008 114 : 347 360.
7. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009 58 : 704 720.
8. Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis. Hepatology 2010 [Epub ahead of print].
9. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000 25 : 187 191.
10. Rallabhandi P, Bell J, Boukhvalova MS, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006 177 : 322 332.
11. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002 186 : 1522 1525.
12. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002 162 : 1028 1032.
13. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008 359 : 1766 1777.
14. Dehus O, Bunk S, von Aulock S, Hermann C. IL-10 release requires stronger toll-like receptor 4-triggering than TNF: a possible explanation for the selective effects of heterozygous TLR4 polymorphism Asp(299)Gly on IL-10 release. Immunobiology 2008 213 : 621 627.
15. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003 197 : 1787 1791.
16. von Aulock S, Schroder NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003 188 : 938 943.
17. Montes AH, Asensi V, Alvarez V, et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006 143 : 404 413.
18. Guarner C, Sola R, Soriano G, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999 117 : 414 419.
19. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986 91 : 1343 1346.
20. Such J, Guarner C, Enríquez J, Rodríguez JL, Serés I, Vilardell F. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988 6 : 80 4.
21. Soriano G, Guarner C, Tomás A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992 103 : 1267 1272.
22. Saab S, Hernández JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009 104 : 993 1001.
23. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007 133 : 818 824.
24. González-Suárez B, Guarner C, Villanueva C, et al. Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2006 18 : 49 55.
25. Senzolo M, Cholongitas E, Burra P, et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009 29 : 1189 1193.
26. Pamer EG. TLR polymorphisms and the risk of invasive fungal infections. N Engl J Med 2008 359 : 1836 1838.
27. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med 2007 204 : 1891 1900.
28. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002 347 : 185 192.
29. Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008 47 : 978 985.
30. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003 37 : 208 217.
31. Schurmann M, Kwiatkowski R, Albrecht M, et al. Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol 2008 152 : 423 431.
32. Jover M, Galán E, Hoyas E, et al. Positional cloning in GLS gene: a microsatellite in the promoter region predicts the risk of hepatic encephalopathy. J Hepatol 2009 50 (Suppl. 1 S277 (abstract).
33. Modi WS, Pollock DD, Mock BA, Banner C, Renauld JC, Van Snick J. Regional localization of the human glutaminase (GLS) and interleukin-9 (IL9) genes by in situ hybridization. Cytogenet Cell Genet 1991 57 : 114 116.
34. Córdoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis 2008 28 : 70 80.
35. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007 46 : 297 306.
36. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009 50 : 1038 1044.
37. Li Y, Chang M, Abar O, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009 51 : 750 757.
38. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009 49 : 960 968.
39. Chan CW, Tsochatzis EA, Carpenter JR, et al. Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. Aliment Pharmacol Ther 2010 31 : 573 582.
40. Somsouk M, Guy J, Biggins SW, et al. Ascites improves upon plus serum sodium model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther 2009 30 : 741 748.
41. Ripoll C, Groszmann R, García-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007 133 : 481 488.
42. Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009 137 : 119 128.